Bexson Biomedical raises $4.8m to advance wearable ketamine treatment for pain and mental health disorders

Bexson Biomedical has successfully raised $4.8 million in Series A funding to accelerate the development of its subcutaneous ketamine treatment platform, aimed at revolutionizing pain ... Read More